|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
1995-2-23
|
|
pubmed:abstractText |
Experience with chemotherapeutic agents in the management of advanced medullary thyroid carcinoma (MTC) is limited and controversial. However, since MTC is a neuroendocrine neoplasm, we considered the possibility that cytotoxic drugs previously used in the treatment of these tumours could also have activity in MTC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
763-5
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:7826911-Adult,
pubmed-meshheading:7826911-Aged,
pubmed-meshheading:7826911-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7826911-Carcinoma, Medullary,
pubmed-meshheading:7826911-Dacarbazine,
pubmed-meshheading:7826911-Female,
pubmed-meshheading:7826911-Fluorouracil,
pubmed-meshheading:7826911-Humans,
pubmed-meshheading:7826911-Leukopenia,
pubmed-meshheading:7826911-Male,
pubmed-meshheading:7826911-Middle Aged,
pubmed-meshheading:7826911-Remission Induction,
pubmed-meshheading:7826911-Thrombocytopenia,
pubmed-meshheading:7826911-Thyroid Neoplasms
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
|
|
pubmed:affiliation |
Department of Clinical and Biological Sciences, Internal Medicine and Medical Oncology, University of Torino, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
